DOCSLIB.ORG

Table 3. Disorders in Which Vitamin B6 Preparations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 3. Disorders in Which Vitamin B6 Preparations Submitted by: Emma Jane Footitt Clinical and Molecular Genetics Unit Institute of Child Health University College London April 2012 Funded by Great Ormond Street Hospital Children’s Charity Submitted in application for the award of Doctor of Philosophy (Ph.D) 1 I, Emma Footitt confirm that the work presented in this thesis is my own. Where information has been derived from other sources I confirm that it has been indicated. Signed…………………………………. …..Date ………………………………… 2 Pyridoxal 5’-phosphate (PLP) is the active form of vitamin B6 in man where it functions as a cofactor for more than 140 enzyme catalysed reactions. Several inherited diseases characterised by seizures have been described which result in an intracellular deficiency of PLP; laboratory measurement of B6 forms an important element in the diagnosis and monitoring of these disorders. A review of PLP measured by HPLC in CSF from patients with neurological disorders showed that variance is greater than indicated by previous studies and the age-related reference limit was revised. This thesis also describes the metabolic disorders that may lead to PLP depletion and examines the relationship of CSF PLP to sulphite accumulation, medications and seizures in patient groups. B6 exists as six different vitamers and is catabolised to 4-pyridoxic acid for urinary excretion. An LC-MS/MS method was developed which could measure all vitameric forms in plasma. Its application to children with B6 responsive seizure disorders showed that patients with inborn errors of metabolism have characteristic B6 profiles which allow them to be differentiated from each other and control populations. PLP is the cofactor for aromatic L-amino acid decarboxylase (AADC) which catalyses the final step in serotonin biosynthesis. This thesis tested the hypothesis that hyperserotonaemia observed in some patients with autism is related to an abnormality in this pathway by investigating the relationship between plasma B6 vitamers, AADC activity and whole blood serotonin in a group of patients and controls. Plasma AADC activity was significantly reduced in autistic subjects; this is considered in the context of current biochemical and molecular understanding and its possible relevance to disease mechanisms is discussed. 3 Declaration 2 Abstract 3 Table of contents 4 List of tables 14 List of figures 18 Abbreviations 23 Acknowledgements 28 Chapter 1: Introduction 1.1 The metabolism, homeostasis and inborn errors of Vitamin B6 30 1.1.1 Chemical structure of B6 vitamers 30 1.1.2 Reactivity of pyridoxal 5 -phosphate 32 1.1.2.1 Reactions of pyridoxal 5’phosphatte with lysine residues and N-terminal amino acids of proteins 32 Enzymes 32 Albumin 32 Haemoglobin 33 1.1.2.2 Reactions of B6 vitamers with free radicals 33 1.1.2.3 Reactions catalysed by pyridoxal 5’-phosphate-enzymes 33 Reactions involving amino acids 33 1.1.2.4 Other pyridoxal 5’phosphate-catalysed reactions 35 1.1.3 Dietary sources of vitamin B6 35 1.1.4 Normal Physiology and Metabolic Pathways 36 1.1.4.1 Salvage Pathway 39 1.1.5 Homeostasis 40 1.1.6 Circadian rhythm of pyridoxal kinase and pyridoxal 5’-phosphate 41 4 1.1.7 Enzymes involved in interconversions of B6 vitamers 42 1.1.7.1 Phosphatases 43 Alkaline phosphatases 43 Tissue non-specific alkaline phosphatase 44 Pyridoxal 5’-phosphate phosphatase 45 PHOSPHO2 45 1.1.7.2 Pyridoxal kinase 45 1.1.7.3 Pyridox(am)ine 5’-phosphate oxidase (PNPO) 46 1.1.8 Enzymes involved in catabolism of B6 vitamers 47 1.1.8.1 Aldehyde oxidase 47 + 1.1.8.2 NAD -dependent aldehyde dehydrogenase 48 1.1.9 Vitamin B6 deficiency states 48 1.1.10 Biochemical assessment of vitamin B6 status 49 1.1.10.1 Indirect Methods 49 1.1.10.2 Direct Methods 50 1.1.11 Vitamin B6 requirements 50 1.1.12 Variation of vitamin B6 metabolism with age 51 1.1.13 Inherited disorders of B6 metabolism 53 1.1.13.1 Antiquitin deficiency (pyridoxine dependent epilepsy, PDE) 58 1.1.13.2 Pyridoxamine 5’-phosphate oxidase (PNPO) deficiency 61 1.1.13.3 Other pyridoxal 5’-phosphate responsive patients 63 1.1.13.4 Hypophosphatasia 64 1.1.13.5 Hyperphosphatasia 64 1.1.13.6 Hyperprolinaemia type II 65 1.1.14 Drugs and Vitamin B6 66 1.1.14.1 Isoniazid (Isonicotinic acid hydrazide) 67 1.1.14.2 L-Dopa 67 1.1.14.3 Methylxanthines including theophylline 68 5 1.1.14.4 Anticonvulsants 68 1.1.15 Pyridoxine and PLP toxicity 69 1.1.15.1 Acute toxicity of pyridoxine 69 1.1.15.2 Chronic toxicity of pyridoxine 69 1.1.15.3 Toxicity of pyridoxal 5’-phosphate 71 1.2 Serotonin metabolism and function 71 1.2.1 Biosynthetic pathway of serotonin 71 1.2.1.1 Tryptophan hydroxylase 1 and 2 (TPH1 and TPH2) 72 1.2.1.2 Aromatic L-amino acid decarboxylase (AADC) 73 1.2.2 Synthesis of melatonin from serotonin 74 1.2.3 Metabolism, storage and mechanisms of action of serotonin 74 1.2.4 Catabolism of serotonin 77 1.2.5 Physiological functions of serotonin 78 1.2.5.1 Neurological and behavioural 79 1.2.5.2 Gastro-intestinal tract 79 1.2.5.3 Cardiovascular system 80 1.2.5.4 Genito-urinary 81 1.2.5.5 Glucose homeostasis 81 1.2.6 Inherited disorders associated with an abnormality of serotonin metabolism 81 1.2.7 Carcinoid syndrome 83 1.2.8 Serotonin abnormalities in autism 84 1.3 Autism 85 1.3.1 Diagnosis of autism 85 1.3.2 Epidemiology of autism 86 1.3.3 Associated medical problems 87 1.3.4 Treatment 88 6 1.3.5 Genetic risk for autism 89 1.3.6 Neuropathology and neuroanatomy 92 1.4 Summary and Aims 93 Chapter 2: Materials and Methods 2.1 Materials 96 2.2 Biochemistry Methods 97 2.2.1 Measurement of PLP in plasma and CSF by reverse phase HPLC 97 2.2.2 Measurement of B6 vitamers and 4-pyridoxic acid by HPLC linked tandem mass spectrometry (LC-MS/MS) 98 2.2.2.1 Sample collection and preparation 98 2.2.2.2 Determination of B6 vitamers and 4- pyridoxic acid 98 2.2.2.3 Quantification of B6 vitamers and 4-pyridoxic acid 101 2.2.3 Aromatic L-amino acid decarboxylase (AADC) activity assay in plasma 101 2.2.3.1 Principle 101 2.2.3.2 Method for L-dopa decarboxylation 102 2.2.3.3 HPLC-ECD for detection of dopamine 102 2.2.3.4 Data analysis and calculation of enzyme activity 103 2.2.4 Whole blood serotonin 104 2.2.4.1 Principle 104 2.4.4.2 Specimen collection, handling and storage 104 2.4.4.3 HPLC conditions and instrumentation 104 2.4.4.4 Preparation of working standard 104 2.4.4.5 Preparation and analysis of subject samples and quality control (QC) 105 2.4.4.6 Quantification of whole blood serotonin in subject samples and QC 105 7 2.2.5 Measurement of 5’-hydroxyindolacetic acid (5-HIAA), homovanillic acid (HVA), 5-methyltetrahydrofolate (5-MTHF) and pterins in cerebrospinal fluid (CSF) by HPLC 105 2.2.5.1 Specimen collection 106 2.2.5.2 Summary of HPLC methodology 106 2.3 Molecular biology methods 107 2.3.1 Extraction of genomic DNA from whole blood and fibroblasts 107 2.3.1.1 Principle 107 2.3.1.2 Method for whole blood and fibroblasts 107 2.3.2 Amplification of genomic DNA of targeted genes by the Polymerase Chain Reaction (PCR) 108 2.3.2.1 PCR conditions 108 2.3.2.2 Analysis of PCR products by agarose gel electrophoresis 109 Materials 109 2.3.3 Sequencing 110 2.3.3.1 Purification of PCR products 110 Principle 110 Method 110 2.3.3.2 Sequencing of PCR products using the Sanger method 110 Principle 110 Method 111 2.3.3.3 DNA precipitation of sequencing reaction 111 Principle 111 Method 112 Chapter 3: Factors affecting the concentration of pyridoxal 5'- phosphate in cerebrospinal fluid 3.1 Introduction 114 3.2 Methods 116 8 3.2.1 Patients and sample collection 116 3.2.2 Biochemical Analysis 118 3.2.3 Molecular Genetic Analysis - Sequencing of the sulphite oxidase gene (SUOX, ENSG00000139531) 118 3.2.4 Statistical Analysis 119 3.2.5 Survey of Patients with Low CSF PLP 120 3.3 Results 120 3.3.1 Effect of Age 122 3.3.2 Effect of seizures, anti-epileptic drugs (AED) and L-Dopa 127 3.3.3 Relationship between PLP and 5-MTHF in CSF 129 3.3.4 Relationship between PLP and BH4 in CSF 130 3.3.5 Survey of patients with CSF PLP below the revised lower reference limit 131 3.3.6 Plasma: CSF PLP ratio 135 3.4 Discussion 136 3.4.1 Epilepsy/seizure disorders 137 3.4.2 Medications 137 3.4.2.1 Antiepileptic drugs (AED) 137 3.4.2.2 L-DOPA 138 3.4.3 Correlation between CSF concentrations of PLP and 5-MTHF 140 3.4.4 Correlation between CSF concentrations of PLP and tetrahydrobiopterin (BH4) 140 3.4.5 CSF PLP in disorders of sulphite accumulation 140 3.4.6 Neonatal seizure disorder with increased plasma: CSF PLP ratio 145 3.4.7 Nutrition 145 3.5 Summary 146 9 Chapter 4: Measurement of plasma B6 vitamers profiles in children with epilepsy using a LC-MS/MS method 4.1 Introduction 148 4.1.1 Laboratory measurement of the B6 vitamers 148 4.1.2 Liquid chromatography mass spectrometry 149 4.1.3 High pressure liquid chromatography (HPLC) 150 4.1.4 Electrospray ionisation 150 4.1.5 Quadrupole analysers 151 4.1.6 Considerations for the measurement of B6 vitamers in plasma 151 4.2 Materials and Method Development 152 4.2.1 Chemical reagents 152 4.2.2 Sample collection & preparation 155 4.2.3 High Pressure Liquid chromatography 155 4.2.3.1 HPLC column selection 155 4.2.3.2 Optimisation of the mobile phase 156 4.2.4 Electrospray ionisation-tandem mass spectrometry (ESI-MS/MS) 159 4.2.4.1 Quantification of B6 vitamers and pyridoxic acid 163 4.3 Results 164 4.3.1 Calibration curves and linearity 164 4.3.2 Precision studies: Intra- and inter-batch coefficient of variance and recovery studies 168 4.3.3 Indicators of accuracy 169 4.3.4 Study of matrix effects 170 4.3.5 Stability of standards and plasma samples 170 4.3.6 Application of the
Load more

Recommended publications
  • Alternative Acetate Production Pathways in Chlamydomonas Reinhardtii During Dark Anoxia and the Dominant Role of Chloroplasts in Fermentative Acetate Productionw
    This article is a Plant Cell Advance Online Publication. The date of its first appearance online is the official date of publication. The article has been edited and the authors have corrected proofs, but minor changes could be made before the final version is published. Posting this version online reduces the time to publication by several weeks. Alternative Acetate Production Pathways in Chlamydomonas reinhardtii during Dark Anoxia and the Dominant Role of Chloroplasts in Fermentative Acetate ProductionW Wenqiang Yang,a,1 Claudia Catalanotti,a Sarah D’Adamo,b Tyler M. Wittkopp,a,c Cheryl J. Ingram-Smith,d Luke Mackinder,a Tarryn E. Miller,b Adam L. Heuberger,e Graham Peers,f Kerry S. Smith,d Martin C. Jonikas,a Arthur R. Grossman,a and Matthew C. Posewitzb a Carnegie Institution for Science, Department of Plant Biology, Stanford, California 94305 b Colorado School of Mines, Department of Chemistry and Geochemistry, Golden, Colorado 80401 c Stanford University, Department of Biology, Stanford, California 94305 d Clemson University, Department of Genetics and Biochemistry, Clemson, South Carolina 29634 e Colorado State University, Proteomics and Metabolomics Facility, Fort Collins, Colorado 80523 f Colorado State University, Department of Biology, Fort Collins, Colorado 80523 ORCID ID: 0000-0001-5600-4076 (W.Y.) Chlamydomonas reinhardtii insertion mutants disrupted for genes encoding acetate kinases (EC 2.7.2.1) (ACK1 and ACK2) and a phosphate acetyltransferase (EC 2.3.1.8) (PAT2, but not PAT1) were isolated to characterize fermentative acetate production. ACK1 and PAT2 were localized to chloroplasts, while ACK2 and PAT1 were shown to be in mitochondria.
    [Show full text]
  • The Aldehyde Dehydrogenase ALDH2*2 Allele Exhibits Dominance Over ALDH2*1 in Transduced Hela Cells
    The aldehyde dehydrogenase ALDH2*2 allele exhibits dominance over ALDH2*1 in transduced HeLa cells. Q Xiao, … , T Johnston, D W Crabb J Clin Invest. 1995;96(5):2180-2186. https://doi.org/10.1172/JCI118272. Research Article Individuals heterozygous or homozygous for the variant aldehyde dehydrogenase (ALDH2) allele (ALDH2*2), which encodes a protein differing only at residue 487 from the normal protein, have decreased ALDH2 activity in liver extracts and experience cutaneous flushing when they drink alcohol. The mechanisms by which this allele exerts its dominant effect is unknown. To study this effect, the human ALDH2*1 cDNA was cloned and the ALDH2*2 allele was generated by site-directed mutagenesis. These cDNAs were transduced using retroviral vectors into HeLa and CV1 cells, which do not express ALDH2. The normal allele directed synthesis of immunoreactive ALDH2 protein (ALDH2E) with the expected isoelectric point. Extracts of these cells contained increased aldehyde dehydrogenase activity with low Km for the aldehyde substrate. The ALDH2*2 allele directed synthesis of mRNA and immunoreactive protein (ALDH2K), but the protein lacked enzymatic activity. When ALDH2*1-expressing cells were transduced with ALDH2*2 vectors, both mRNAs were expressed and immunoreactive proteins with isoelectric points ranging between those of ALDH2E and ALDH2K were present, indicating that the subunits formed heteromers. ALDH2 activity in these cells was reduced below that of the parental ALDH2*1-expressing cells. Thus, the ALDH2*2 allele is sufficient to cause ALDH2 deficiency in vitro. Find the latest version: https://jci.me/118272/pdf The Aldehyde Dehydrogenase ALDH2*2 Allele Exhibits Dominance over ALDH2*1 in Transduced HeLa Cells Qing Xiao, * Henry Weiner,* Timothy Johnston,* and David W.
    [Show full text]
  • Combined Treatment of Isoflavone Supplementation and Exercise
    Yoon et al. Journal of the International Society of Sports Nutrition 2014, 11:29 http://www.jissn.com/content/11/1/29 RESEARCH ARTICLE Open Access Combined treatment of isoflavone supplementation and exercise restores the changes in hepatic protein expression in ovariectomized rats - a proteomics approach Sun Yoon1, Joomin Lee2 and Seung-Min Lee1* Abstract Background: Postmenopausal women experience adverse physiological changes caused by estrogen deprivation. Here, we hypothesized that the administration of isoflavone, a phytoestrogn, and/or physical exercise could reverse changes in the levels of hepatic enzymes disturbed by loss of estrogen to ameliorate postmenopause-related health problems. Methods: Thirty-week-old female Sprague–Dawley rats were divided into five groups: a sham-operated (SHAM) group, ovariectomized groups on a regular diet with exercise (EXE) and without exercise (OVX), and ovariectomized groups on an isoflavone supplemented diet with (ISO + EXE) and without exercise (ISO). Proteomic tools were employed to identify candidate hepatic proteins that were differentially expressed among the five animal groups. Results: INMT was detected in the SHAM but not in all of the ovariectomized rats. Seven proteins (PPIA, AKR1C3, ALDH2, PSME2, BUCS1, OTC, and GAMT) were identified to have differential expression among the groups. When compared to the SHAM group, the ovariectomy elevated the levels of PPIA, BUCS1, PSME2, AKR1C3, and GAMT while decreasing ALDH2 and OTC. Among these OVX-induced changes, OVX-increased BUCS1 and GAMT levels were noticeably decreased by ISO or EXE and further greatly down-regulated by ISO + EXE. In the case of PSME2, ISO and EXE further increased OVX-upregulated expression levels but ISO + EXE greatly reduced OVX-increased levels.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • ALDH2) in Escherichia Coli Nissle 1917 for Oral ​ ​ Delivery in ALDH2-Deficient Individuals
    bioRxiv preprint doi: https://doi.org/10.1101/674606; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Recombinant Expression of Aldehyde Dehydrogenase 2 (ALDH2) in Escherichia coli Nissle 1917 for Oral ​ ​ Delivery in ALDH2-Deficient Individuals Authors Tim Ho, Catherine Chang, Justin Wu, Iris Huang, Leona Tsai, Justin Lin, Emily Tai, Caroline Chou, Justin Yang, Yvonne Wei, Catherine Yeh, William Chen, Dylan Lu, Charlotte Chou, Longan Su, Nicole Chang, Colin Huang, Chloe Wang, Paul Abrena, Christy Cheung, Cassandra Yeh, Shantih Whiteford, Phoebe Chen, Austin Huang, Aire Wu, Benjamin Wei, Eugene Kao, Nicholas Lin, Anna Chang, Jake Yang, Yasmin Lin, Sean Tsao, Nicholas Ward, Teresa Chiang, Jude Clapper* Taipei American School, Taipei City, Taiwan. *Corresponding author: [email protected] Abstract Turning red after consuming alcohol may seem like a mere social inconvenience. Yet, this flushing response is caused by an accumulation of acetaldehyde, a carcinogenic intermediate of alcohol metabolism. Aldehyde dehydrogenase 2 (ALDH2) deficiency, the result of a point mutation, produces a less efficient ALDH2. The resulting accumulation of acetaldehyde greatly increases the risk of developing esophageal and head and neck cancers. In this study, we produced recombinant ALDH2 in the probiotic E. coli Nissle 1917, which successfully reduces acetaldehyde levels in ​ ​ simulated oral conditions. Packaged in a hard candy, the ALDH2-probiotic would remain in the mouth to specifically target salivary acetaldehyde. Using mathematical modeling, we also determined how much recombinant ALDH2 is needed to reduce elevated acetaldehyde levels.
    [Show full text]
  • Amyloid Like Aggregates Formed by the Self-Assembly of Proline And
    Please do not adjust margins Journal Name ARTICLE Amyloid like aggregates formed by the self-assembly of proline and Hydroxyproline Bharti Koshtia, Ramesh Singh Chilwalb, Vivekshinh Kshtriyaa, Shanka Walia c, Dhiraj Bhatiac, K.B. Joshib* and Nidhi Goura* a Department of Chemistry, Indrashil University, Mehsana, Gujarat, India b Department of Chemistry, Dr. Hari Singh Gour, Sagar University, Madhya Pradesh, India c Biological Engineering Discipline, Indian Institute of Technology Gandhinagar, Gujarat, India Abstract: Single amino acid based self-assembled structures have gained a lot of interest recently owing to their pathological significance in metabolite disorders. There is plethora of significant research work which illustrate amyloid like characteristics of assemblies formed by aggregation of single amino acids like Phenylalanine, Tyrosine, Tryptophan, Cysteine and Methionine and its implications in pathophysiology of single amino acid metabolic disorders like phenylketonuria, tyrosinemia, hypertryptophanemia, cystinuria and hypermethioninemia respectively. Hence, studying aggregation behaviour of single amino acids is very crucial to assess the underlying molecular mechanism behind metabolic disorders. In this manuscript we report for the very first time the aggregation properties of non-aromatic single amino acids Hydroxy-proline and Proline. The morphologies of these were studied extensively by Optical microscopy (OM), ThT binding fluorescence microscopy, Scanning Electron Microscopy (SEM) and Atomic force microscopy (AFM). It can be assessed that these amino acids form globular structures at lower concentrations and gradually changes to tape like structures on increasing the This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1 Please do not adjust margins Please do not adjust margins Journal Name ARTICLE concentration as assessed by AFM.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Neutral Amino Acids in the Urine [5-7]
    "This is a non-final version of an article published in final form in Current Opinion in Nephrology and Hypertension 22.5 (2013): 539-544 ". Epithelial neutral amino acid transporters, lessons from mouse models Stefan Bröer Research School of Biology, Australian National University Author of correspondence: Name: Stefan Bröer Address: Research School of Biology Linnaeus Way 134 Australian National University Canberra, ACT 0200, Australia Telephone number: +61-2-6125-2540 Email address: [email protected] Abstract (200 words max.): Purpose of review: Epithelial neutral amino acid transporters have been identified at the molecular level in recent years. Mouse models have now established the crucial role of these transporters for systemic amino acid homeostasis. The review summarises recent progress in this field. Recent findings: Epithelial neutral amino acid transporters play an important role in the homeostasis of neutral amino acid levels in the body. They are important for the maintenance of body weight, muscle mass and serve as fuels. They also serve a role in providing nutrients to epithelial cells. Changes of plasma amino acid levels are not necessarily correlated to the amino acids appearing in the urine, changes to organ amino acid metabolism need to be taken into account. Summary: Genetic deletion of neutral amino acid transporters provides insight into their role in protein nutrition and homestasis. Keywords: Protein nutrition, intestine, kidney Abbreviations: dss, dextran-sulphate; hpd, high protein diet; nd, normal diet Introduction The majority of epithelial amino acid transporters have been identified in recent years [1-3]. Many of these are expressed in both intestinal and renal epithelia (Fig.
    [Show full text]
  • Hartnup Disease
    Hartnup disease Description Hartnup disease is a condition caused by the body's inability to absorb certain protein building blocks (amino acids) from the diet. As a result, affected individuals are not able to use these amino acids to produce other substances, such as vitamins and proteins. Most people with Hartnup disease are able to get the vitamins and other substances they need with a well-balanced diet. People with Hartnup disease have high levels of various amino acids in their urine ( aminoaciduria). For most affected individuals, this is the only sign of the condition. However, some people with Hartnup disease have episodes during which they exhibit other signs, which can include skin rashes; difficulty coordinating movements ( cerebellar ataxia); and psychiatric symptoms, such as depression or psychosis. These episodes are typically temporary and are often triggered by illness, stress, nutrient-poor diet, or fever. These features tend to go away once the trigger is remedied, although the aminoaciduria remains. In affected individuals, signs and symptoms most commonly occur in childhood. Frequency Hartnup disease is estimated to affect 1 in 30,000 individuals. Causes Hartnup disease is caused by mutations in the SLC6A19 gene. This gene provides instructions for making a protein called B0AT1, which is primarily found embedded in the membrane of intestine and kidney cells. The function of this protein is to transport certain amino acids into cells. In the intestines, amino acids from food are transported into intestinal cells then released into the bloodstream so the body can use them. In the kidneys, amino acids are reabsorbed into the bloodstream instead of being removed from the body in urine.
    [Show full text]
  • Diagnosis and Treatment of Tyrosinosis
    Arch Dis Child: first published as 10.1136/adc.43.231.540 on 1 October 1968. Downloaded from Arch. Dis. Childh., 1968, 43, 540. Diagnosis and Treatment of Tyrosinosis ANGELA FAIRNEY, DOROTHY FRANCIS, R. S. ERSSER, J. W. T. SEAKINS, and DENNIS COTTOM From the Department ofChemical Pathology, Institute ofChild Health and The Hospitalfor Sick Children, London W.C.1 This paper describes the diagnosis of tyrosinosis A clean specimen of urine gave a deposit showing scanty in a girl aged 10 months. Her subsequent pro- pus cells, with a mixed growth on culture. X-rays gress after the institution of a diet low in phenyl- showed changes of rickets in the knees and anterior alanine and tyrosine has been good, and details of ends of the ribs and femora. An intravenous pyelogram showed enlarged kidneys with prompt excretion of the her treatment are discussed. dye; there was stretching of the calyces in the left and Tyrosinosis is an inherited metabolic disorder possibly in the right, which was suggestive of the adult characterized by cirrhosis, severe hypophosphat- type of polycystic disease. There was no clear sign of a aemic rickets, renal tubular defects, and a derange- focal lesion or paroxysmal features on the EEG. ment of tyrosine metabolism. The metabolic Biochemical results are listed in Table I. With the products arising from the deranged tyrosine exception of tyrosine, the plasma amino acid pattern metabolism point to a lack of p-hydroxyphenyl- was within the normal range, and in particular methio- pyruvate oxidase (Halvorsen, 1967). nine was never raised (normal approx.
    [Show full text]